ReviewCurrent fungal infection reports2016
Therapeutic Drug Monitoring of Posaconazole: an Update.
Review in Current fungal infection reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04619147 (Invasive Fungal Infections in Patients Following Stem Cell Transplant), which is not on this map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Invasive Fungal Infections in Patients Following Stem Cell Transplant
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.BMC infectious diseases · 2018Pooled it
- First report of proven Fusarium brachygibbosum sinusitis in a paediatric patient with acute myeloblastic leukaemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Therapeutic drug monitoring in leukemia: global research trends and implications for clinical pharmacy practice-a bibliometric analysis.International journal of clinical pharmacy · 2026Review
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- Real-world study of posaconazole tablets for the prophylaxis of invasive fungal disease in patients with end-stage liver disease.BMC gastroenterology · 2026Article
- Alginate-Polymethacrylate Hybrid Microparticles as Multi-Unit Enteric Drug Carriers for Posaconazole.Pharmaceutics · 2026Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- The Unnoticed Threat: Clinical Characteristics, Risk Factors, and Outcome of Mucormycosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2025Review
- Review
- Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2025Article
- Assessment of the Effective Dose of Isavuconazole, Itraconazole, Posaconazole, and Voriconazole to Achieve Goal Serum Concentrations in Pediatric Patients at a Single Center.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China.Frontiers in pharmacology · 2025Article
- Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies.Drug design, development and therapy · 2025Article
- Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients.Antimicrobial agents and chemotherapy · 2024Article
- Development of an HPLC-UV method for quantification of posaconazole in low-volume plasma samples: design of experiments and machine learning models.BMC chemistry · 2024Article
- Approaches for posaconazole therapeutic drug monitoring and their clinical benefits.European journal of clinical pharmacology · 2024Review
- Article
- ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Hard Gelatin Capsules with Alginate-Hypromellose Microparticles as a Multicompartment Drug Delivery System for Sustained Posaconazole Release.International journal of molecular sciences · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.